← Back to patent-cliff list
Tasurgratinib
Tier C — Watch / tradeTasurgratinib
Eisai Co., Ltd.
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR1, FGFR3, FGFR2
Brand：TASFYGO
Indications (approved)：Biliary tract cancer, Bile duct cancer
Regional status
US
-
EU
No progress
2020-09-09
China
Approved
2026-09-02
Japan
Approved
2024-09-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tasurgratinib?
Approved indications include: Biliary tract cancer, Bile duct cancer.
When does the Tasurgratinib patent expire?
No public expiry year is available for Tasurgratinib yet; this page updates once verified.
How do I get a quote for Tasurgratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27